pramipexole has been researched along with risperidone in 8 studies
| Studies (pramipexole) | Trials (pramipexole) | Recent Studies (post-2010) (pramipexole) | Studies (risperidone) | Trials (risperidone) | Recent Studies (post-2010) (risperidone) |
|---|---|---|---|---|---|
| 1,103 | 219 | 517 | 6,924 | 1,505 | 2,477 |
| Protein | Taxonomy | pramipexole (IC50) | risperidone (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.015 | |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.0027 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.0097 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 5.2734 | |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | 4.1901 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.0167 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.0991 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.026 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.0096 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.799 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 0.479 | |
| Histamine H2 receptor | Homo sapiens (human) | 1.483 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.01 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.0016 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.0057 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.799 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.0027 | |
| 5-hydroxytryptamine receptor 2C | Mus musculus (house mouse) | 0.0015 | |
| Alpha-1A adrenergic receptor | Homo sapiens (human) | 0.0105 | |
| 5-hydroxytryptamine receptor 2A | Mus musculus (house mouse) | 0.0015 | |
| Histamine H1 receptor | Homo sapiens (human) | 0.4515 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.024 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.023 | |
| D(2) dopamine receptor | Mus musculus (house mouse) | 0.023 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0154 | |
| 5-hydroxytryptamine receptor 2B | Mus musculus (house mouse) | 0.0015 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.6303 | |
| 5-hydroxytryptamine receptor 1A | Mus musculus (house mouse) | 0.43 | |
| Nuclear receptor subfamily 3 group C member 3 | Bos taurus (cattle) | 4.1901 | |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 1.6 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Davidson, M; Levy, A; Weizer, M | 1 |
| Barsoum, P; Graff-Guerrero, A; Houle, S; Kapur, S; Mamo, D; Marcon, H; Mizrahi, R; Rusjan, P; Shammi, CM; Wilson, AA | 1 |
| Ishitobi, M; Kosaka, H; Murata, T; Shukunami, K; Wada, Y | 1 |
| Del Castillo, RM; MartÃnez, A; Ramos, E | 1 |
2 review(s) available for pramipexole and risperidone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[New antipsychotic drugs].
Topics: Antipsychotic Agents; Benzodiazepines; Benzothiazoles; Clinical Trials as Topic; Dibenzothiazepines; Humans; Imidazoles; Indoles; Olanzapine; Piperazines; Pirenzepine; Pramipexole; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Thiazoles | 1997 |
1 trial(s) available for pramipexole and risperidone
| Article | Year |
|---|---|
The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study With [11C]-(+)-PHNO.
Topics: Adult; Antipsychotic Agents; Basal Ganglia; Benzodiazepines; Benzothiazoles; Binding, Competitive; Carbon Radioisotopes; Caudate Nucleus; Clozapine; Dopamine Agonists; Dopamine Antagonists; Double-Blind Method; Female; Globus Pallidus; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Olanzapine; Oxazines; Positron-Emission Tomography; Pramipexole; Putamen; Raclopride; Receptors, Dopamine D2; Receptors, Dopamine D3; Risperidone; Schizophrenia | 2009 |
5 other study(ies) available for pramipexole and risperidone
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Adjunctive treatment with low-dosage pramipexole for risperidone-associated hyperprolactinemia and sexual dysfunction in a male patient with schizophrenia.
Topics: Adult; Benzothiazoles; Drug Therapy, Combination; Erectile Dysfunction; Humans; Hyperprolactinemia; Male; Pramipexole; Risperidone; Schizophrenia | 2011 |
Interaction of graphene with antipsychotic drugs: Is there any charge transfer process?
Topics: Antipsychotic Agents; Dopamine; Graphite; Humans; Models, Chemical; Pramipexole; Receptors, Dopamine D2; Risperidone | 2021 |